Table 2.

Logistic regression analysis of association of radiation clinical trial characteristics and inclusion of a cardiac primary or secondary endpoint.

Variable	Odds Ratio	95% CI	p-value
Breast vs. Non-Breast disease site	2.30	0.75-5.25	0.15
Phase III vs. Phase II	2.12	0.64-7.08	0.22
Use of Concurrent Chemotherapy (Yes vs. No)	0.41	0.13-1.29	0.13
Trial Size (>220 patients vs. ≤ 220 patients)	1.20	0.39-3.66	0.75
Trial Duration (>6.5 years vs. ≤ 6.5 years)	0.43	0.13-1.42	0.17
Post-Darby Era vs. Pre-Darby Era	1.57	0.47-5.25	0.46